BioLineRx Interest Income from 2010 to 2025

BLRX Stock

USD 3.41 0.16 4.48%

BioLineRx Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2025. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

535 K

Current Value

434 K

Quarterly Volatility

204 K

Covid

Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 2.6 M or Selling General Administrative of 20.1 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.44. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.

Check out the analysis of BioLineRx Correlation against competitors.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Interest Income Growth Pattern

Below is the plot of the Interest Income of BioLineRx over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. BioLineRx's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Interest Income

Timeline

BioLineRx Interest Income Regression Statistics

	Arithmetic Mean	1,310,969
	Geometric Mean	1,101,815
	Coefficient Of Variation	52.49
	Mean Deviation	610,973
	Median	1,658,000
	Standard Deviation	688,171
	Sample Variance	473.6B
	Range	2.2M
	R-Value	0.01
	Mean Square Error	507.3B
	R-Squared	0.0001
	Significance	0.97
	Slope	1,586
	Total Sum of Squares	7.1T

BioLineRx Interest Income History

	2025	2.4 M
	2024	2.3 M
	2023	2 M
	2022	694 K
	2021	559 K
	2020	236 K
	2019	777 K

Other Fundumenentals of BioLineRx

Net Interest Income

BioLineRx Interest Income component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Net Tangible Assets	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.53	0.6	0.78	0.76	0.49	0.75	0.69	0.65	0.71	0.57	-0.79	0.01	0.86	0.65	0.67	0.62	-0.11	-0.3	0.65	-0.19	-0.19
Total Stockholder Equity	0.53		-0.3	0.14	0.51	-0.45	0.24	-0.16	0.33	-0.03	-0.11	0.02	-0.06	0.52	-0.2	0.49	-0.2	0.68	0.46	-0.19	0.38	0.38
Accounts Payable	0.6	-0.3		0.75	0.39	0.96	0.59	0.9	0.47	0.8	0.76	-0.88	0.03	0.45	0.91	0.24	0.89	-0.67	-0.73	0.89	-0.71	-0.71
Long Term Debt	0.78	0.14	0.75		0.45	0.7	0.85	0.8	0.45	0.79	0.7	-0.86	0.15	0.52	0.82	0.3	0.79	-0.23	-0.52	0.77	-0.42	-0.42
Short Term Investments	0.76	0.51	0.39	0.45		0.28	0.29	0.49	0.52	0.55	0.55	-0.54	-0.13	0.95	0.29	0.94	0.25	0.03	0.01	0.47	-0.16	-0.16
Total Liab	0.49	-0.45	0.96	0.7	0.28		0.49	0.92	0.32	0.81	0.73	-0.83	0.04	0.36	0.89	0.17	0.87	-0.75	-0.74	0.91	-0.75	-0.75
Intangible Assets	0.75	0.24	0.59	0.85	0.29	0.49		0.54	0.61	0.47	0.52	-0.78	0.1	0.35	0.74	0.12	0.74	-0.27	-0.63	0.49	-0.1	-0.1
Common Stock	0.69	-0.16	0.9	0.8	0.49	0.92	0.54		0.32	0.96	0.66	-0.9	-0.08	0.61	0.88	0.42	0.84	-0.48	-0.51	1.0	-0.67	-0.67
Property Plant Equipment	0.65	0.33	0.47	0.45	0.52	0.32	0.61	0.32		0.22	0.56	-0.57	-0.14	0.47	0.51	0.34	0.52	-0.31	-0.52	0.27	-0.11	-0.11
Current Deferred Revenue	0.71	-0.03	0.8	0.79	0.55	0.81	0.47	0.96	0.22		0.59	-0.82	-0.05	0.69	0.78	0.52	0.73	-0.26	-0.3	0.97	-0.61	-0.61
Net Debt	0.57	-0.11	0.76	0.7	0.55	0.73	0.52	0.66	0.56	0.59		-0.71	0.24	0.45	0.65	0.34	0.62	-0.52	-0.65	0.64	-0.53	-0.53
Retained Earnings	-0.79	0.02	-0.88	-0.86	-0.54	-0.83	-0.78	-0.9	-0.57	-0.82	-0.71		0.13	-0.61	-0.92	-0.44	-0.89	0.51	0.65	-0.87	0.44	0.44
Net Receivables	0.01	-0.06	0.03	0.15	-0.13	0.04	0.1	-0.08	-0.14	-0.05	0.24	0.13		-0.15	-0.14	-0.19	-0.16	-0.04	-0.11	-0.07	0.07	0.07
Total Current Assets	0.86	0.52	0.45	0.52	0.95	0.36	0.35	0.61	0.47	0.69	0.45	-0.61	-0.15		0.4	0.93	0.36	0.03	0.02	0.6	-0.22	-0.22
Short Term Debt	0.65	-0.2	0.91	0.82	0.29	0.89	0.74	0.88	0.51	0.78	0.65	-0.92	-0.14	0.4		0.15	0.99	-0.61	-0.77	0.87	-0.59	-0.59
Net Tangible Assets	0.67	0.49	0.24	0.3	0.94	0.17	0.12	0.42	0.34	0.52	0.34	-0.44	-0.19	0.93	0.15		0.1	0.12	0.2	0.42	-0.03	-0.03
Short Long Term Debt	0.62	-0.2	0.89	0.79	0.25	0.87	0.74	0.84	0.52	0.73	0.62	-0.89	-0.16	0.36	0.99	0.1		-0.62	-0.79	0.82	-0.57	-0.57
Net Invested Capital	-0.11	0.68	-0.67	-0.23	0.03	-0.75	-0.27	-0.48	-0.31	-0.26	-0.52	0.51	-0.04	0.03	-0.61	0.12	-0.62		0.88	-0.47	0.42	0.42
Net Working Capital	-0.3	0.46	-0.73	-0.52	0.01	-0.74	-0.63	-0.51	-0.52	-0.3	-0.65	0.65	-0.11	0.02	-0.77	0.2	-0.79	0.88		-0.48	0.38	0.38
Capital Stock	0.65	-0.19	0.89	0.77	0.47	0.91	0.49	1.0	0.27	0.97	0.64	-0.87	-0.07	0.6	0.87	0.42	0.82	-0.47	-0.48		-0.69	-0.69
Long Term Debt Total	-0.19	0.38	-0.71	-0.42	-0.16	-0.75	-0.1	-0.67	-0.11	-0.61	-0.53	0.44	0.07	-0.22	-0.59	-0.03	-0.57	0.42	0.38	-0.69		1.0
Capital Surpluse	-0.19	0.38	-0.71	-0.42	-0.16	-0.75	-0.1	-0.67	-0.11	-0.61	-0.53	0.44	0.07	-0.22	-0.59	-0.03	-0.57	0.42	0.38	-0.69	1.0

Click cells to compare fundamentals

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	2.3 M	2.4 M
Net Interest Income	-145.8 K	-153.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioLineRx Interest Income from 2010 to 2025

Latest BioLineRx's Interest Income Growth Pattern

BioLineRx Interest Income Regression Statistics

BioLineRx Interest Income History

Other Fundumenentals of BioLineRx

BioLineRx Interest Income component correlations

About BioLineRx Financial Statements

Also Currently Popular

Additional Tools for BioLineRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY